Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

(2022) Emma K. Accorsi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

(2022) Samuel M. S. Cheng et al.   NATURE MEDICINE

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

(2022) Eddy Pérez-Then et al.   NATURE MEDICINE

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study

(2022) Jing Lian Suah et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

(2021) Ital Nemet et al.   NEW ENGLAND JOURNAL OF MEDICINE